Professor Constantine (Con) Tam
MBBS (Hons), MD, FRACP, FRCPA
Research & Education Lead, Haematology
Program Lead for CLL and Low-Grade Lymphoma, Peter MacCallum Cancer Centre and Professor of Haematology, University of Melbourne
View alliance profile
Professor Con Tam (MBBS (Hons), MD, FRACP, FRCPA) is Program Lead for Chronic Lymphocytic Leukemia (CLL) and Low-Grade Lymphoma at Peter MacCallum Cancer Centre. He is Professor of Haematology, the University of Melbourne where he teaches and supervises PhD students.
Professor Tam is the global lead for the novel BTK inhibitor zanubrutinib, and he completed the first study in the world to combine ibrutinib and venetoclax. Since 2012, he has received over $18 million in grants. He has authored 211 papers, with over 7,000 Web of ScienceTM citations.
In support of his keen interest in the biology and treatment of blood cancers Professor Tam is Associate Editor at Blood Advances, the open-access journal of the American Society of Hematology. Earlier in his career, Professor Tam trained in medicine and haematology and worked at St Vincent’s Hospital Melbourne and The Alfred before completing a two-year CLL fellowship at the MD Anderson Cancer Center in Texas, USA.
In May 2021, Professor Tam was appointed VCCC Alliance Research & Education Lead, Haematology. In this role he will provide leadership and strategic direction for the research and education aspects of the haematological malignancies stream, with the goal of embedding the latest research and evidence more quickly into routine clinical practice.